公开(公告)号：US20240091352A1

公开(公告)日：2024-03-21

申请号：US18175894

申请日：2023-02-28

Applicant: GENMAB A/S

Inventor： Esther BREIJ ,  David SATIJN ,  Edward Norbert VAN DEN BRINK ,  Dennis VERZIJL ,  Rob N. DE JONG ,  Paul PARREN ,  Riemke VAN DIJKHUIZEN RADERSMA

IPC: A61K39/395 ,  A61K47/68 ,  C07K16/28 ,  C07K16/30

CPC classification number: A61K39/39558 ,  A61K47/6801 ,  A61K47/6855 ,  A61K47/6857 ,  A61K47/6869 ,  C07K16/2863 ,  C07K16/3061 ,  A61K2039/505

Abstract: The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.

公开(公告)号：US11845805B2

公开(公告)日：2023-12-19

申请号：US17558430

申请日：2021-12-21

Applicant: GENMAB A/S

Inventor： Brian Elliott ,  Tahamtan Ahmadi ,  Christopher W. L. Chiu ,  Esther C. W Breij ,  Ida Hiemstra ,  Maria N. Jure-Kunkel

IPC: A61P35/00 ,  A61K31/475 ,  A61K31/573 ,  A61K31/675 ,  A61K31/704 ,  C07K16/28 ,  A61K39/395 ,  A61K39/00

CPC classification number: C07K16/2887 ,  A61K31/475 ,  A61K31/573 ,  A61K31/675 ,  A61K31/704 ,  A61K39/3955 ,  A61P35/00 ,  C07K16/2809 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/565

Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., previously untreated, high-risk DLBCL) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).

公开(公告)号：US20230374131A1

公开(公告)日：2023-11-23

申请号：US18109708

申请日：2023-02-14

Applicant: Genmab A/s

Inventor： Edward Norbert VAN DEN BRINK ,  Joost J. Neijssen ,  Aran Frank Labrijn ,  Joyce Meesters ,  Janine Schuurman ,  Isil Altintas ,  Paul Parren ,  Rik Rademaker

IPC: C07K16/28 ,  C07K16/32 ,  C07K16/10 ,  C07K16/42 ,  G01N33/68

CPC classification number: C07K16/2809 ,  C07K16/2887 ,  C07K16/32 ,  C07K16/1063 ,  C07K16/2863 ,  C07K16/2896 ,  C07K16/4241 ,  G01N33/6872 ,  A61K2039/505

Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.

公开(公告)号：US20230365714A1

公开(公告)日：2023-11-16

申请号：US18029472

申请日：2021-10-01

Applicant: GENMAB A/S

Inventor： Louise Koopman ,  Patrick ENGELBERTS ,  David SATIJN ,  Jan Hermen DANNENBERG

IPC: C07K16/46 ,  A61P35/00

CPC classification number: C07K16/468 ,  A61P35/00 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/24 ,  C07K2317/35 ,  C07K2317/92

Abstract: The present invention relates to antibodies binding to ROR2, including bispecific antibodies binding to ROR2 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

公开(公告)号：US11814411B2

公开(公告)日：2023-11-14

申请号：US17144591

申请日：2021-01-08

Applicant: BIONTECH SE ,  GENMAB A/S

Inventor： Ugur Sahin ,  Friederike Gieseke ,  Isil Altintas ,  David Satijn ,  Paul Parren

IPC: C07K16/28

CPC classification number: C07K16/2878 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/92

Abstract: The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.

公开(公告)号：US20230257479A1

公开(公告)日：2023-08-17

申请号：US17642488

申请日：2020-09-11

Applicant: GENMAB A/S

Inventor： David SATIJN ,  Esther C.W. BREIJ ,  Bart E.C.G. DE GOEIJ ,  Kristel KEMPER ,  Patrick ENGELBERTS ,  Edward N. VAN DEN BRINK ,  Rik RADEMAKER ,  Dennis VERZIJL ,  Sjeng HORBACH ,  Paul PARREN ,  Reshma Abdulla RANGWALA ,  Sri GHATTA ,  Ruud BRAKENHOFF ,  Rieneke VAN DE VEN

IPC: C07K16/30 ,  A61P35/00 ,  A61P1/00

CPC classification number: C07K16/30 ,  A61P1/00 ,  A61P35/00 ,  A61K2039/505

Abstract: The present invention relates to multispecific antibodies binding to 5T4 and CD3 for use in the treatment of cancer selected from the group consisting of esophageal cancer, Non-small Cell Lung Cancer (NSCLC) and Squamous Cell Carcinoma of the Head and Neck (SCCHN).

公开(公告)号：US20230241211A1

公开(公告)日：2023-08-03

申请号：US18160386

申请日：2023-01-27

Applicant: GENMAB A/S

Inventor： Christopher W. L. CHIU ,  Mariana Cota STIRNER ,  Minh H. DINH ,  Iliana Edith SZAFER-GLUSMAN

IPC: A61K39/395 ,  A61K31/454 ,  A61K31/519 ,  A61P35/00 ,  A61P7/00

CPC classification number: A61K39/3955 ,  A61K31/454 ,  A61K31/519 ,  A61P35/00 ,  A61P7/00 ,  A61K2039/545

Abstract: Provided are methods of clinical treatment of Diffuse Large B-cell Lymphoma (for example, relapsed and/or refractory Diffuse Large B-cell Lymphoma) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with lenalidomide or ibrutinib and lenalidomide.

公开(公告)号：US20230089969A1

公开(公告)日：2023-03-23

申请号：US17817033

申请日：2022-08-03

Applicant: GENMAB A/S ,  BioNTech SE

Inventor： Isil ALTINTAS ,  David SATIJN ,  Rik RADEMAKER ,  Paul PARREN ,  Friederike GIESEKE ,  Ugur SAHIN

IPC: C07K16/28 ,  A61K39/395 ,  G01N33/569

Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.

公开(公告)号：US20230087745A1

公开(公告)日：2023-03-23

申请号：US17821837

申请日：2022-08-24

Applicant: GENMAB A/S ,  BIONTECH SE

Inventor： Isil ALTINTAS ,  David SATIJN ,  Rik RADEMAKER ,  Paul PARREN ,  Ugur SAHIN ,  Friederike GIESEKE ,  Alexander MUIK ,  Christian GRUNWITZ ,  Edward VAN DEN BRINK ,  Dennis VERZIJL

IPC: C07K16/28

Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.

公开(公告)号：US20230087164A1

公开(公告)日：2023-03-23

申请号：US17795318

申请日：2021-02-04

Applicant: GENMAB A/S ,  BIONTECH SE

Inventor： Ugur SAHIN ,  Alexander MUIK ,  Isil ALTINTAS ,  Ulf FORSSMANN ,  Kate SASSER ,  Maria JURE-KUNKEL ,  Manish GUPTA

IPC: C07K16/28 ,  A61P35/00

Abstract: The present invention relates to a method for reducing or preventing progression of a tumor or treating cancer. The method comprises administering to a subject, a binding agent comprising a first binding region binding to human CD137 and a second binding region binding to human PD-L1. The amount of binding agent administered in each treatment cycle is preferably about 0.3-5 mg/kg body weight or about 25-400 mg in total.